Physician profile
Adele Haimovic
NPI 1518227800
$2,997.40
in general payments reported to CMS, 2019-2025
25 companies · $1,658 in 2025
The $1,658 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2023: $678 · 2024: $488 · 2025: $1,658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,729 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,728.58 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $478.32 | 2023-2025 | |
| Galderma Laboratories, L.P. | $414.17 | 2019-2025 | Nemluvio, Aklief |
| Incyte Corporation | $367.47 | 2023-2025 | Opzelura |
| Almirall LLC | $316.97 | 2023-2025 | Seysara |
| Sun Pharmaceutical Industries INC. | $254.33 | 2023-2025 | Ilumya |
| E.R. Squibb & Sons, L.L.C. | $170.93 | 2023-2025 | Sotyktu |
| Janssen Biotech, INC. | $121.92 | 2023 | Tremfya, Simponi Aria, Remicade |
| Journey Medical Corporation | $117.65 | 2023-2025 | |
| Amgen INC. | $105.22 | 2023-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $87.82 | 2024-2025 | Cabtreo, Siliq |
| Leo Pharma INC. | $70.02 | 2023-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $69.45 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $66.99 | 2023-2025 | Zoryve |
| Merz North America, INC. | $59.61 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $53.58 | 2023-2025 | Libtayo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $33.62 | 2023 | |
| Lilly USA, LLC | $32.27 | 2023 | Taltz, Olumiant |
| Mayne Pharma Commercial LLC | $32.11 | 2025 | |
| Ucb, INC. | $29.85 | 2025 | Bimzelx |
| Sensus Healthcare, INC. | $26.67 | 2024 | |
| Novartis Pharmaceuticals Corporation | $20.57 | 2025 | |
| Botanix Sb INC | $17.96 | 2025 | Sofdra |
| Lnhc, INC | $17.77 | 2025 | Zelsuvmi |
| Krystal Biotech INC | $16.62 | 2025 | Vyjuvek |
| Organon LLC | $15.51 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adele Haimovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.